Your browser doesn't support javascript.
Ultrapotent neutralizing antibodies against SARS-CoV-2 with a high degree of mutation resistance.
Zou, Jia; Li, Li; Zheng, Peiyi; Liang, Wenhua; Hu, Siyi; Zhou, Shuaixiang; Wang, Yanqun; Zhao, Jincun; Yuan, Daopeng; Liu, Lu; Wu, Dongdong; Xu, Mengqiu; Zhang, Fangfang; Zhu, Mengzhu; Wu, Zhihai; Cao, Xiaochao; Ni, Meng; Ling, Xiaomin; Wu, Yue; Kuang, Zhihui; Hu, Moyan; Li, Jianfeng; Li, Xue; Guo, Xiling; Xu, Tianmin; Jiang, Haiping; Gao, Changshou; Yu, Michael; Liu, Junjian; Zhong, Nanshan; Zhou, Jianfeng; Huang, Jian-An; Jin, Tengchuan; He, Jianxing.
  • Zou J; Guangzhou Laboratory, Guangzhou International Biotech Island, Guangzhou, China.
  • Li L; Innovent Biologics (Suzhou) Co., Ltd., Suzhou, Jiangsu, China.
  • Zheng P; Innovent Biologics (Suzhou) Co., Ltd., Suzhou, Jiangsu, China.
  • Liang W; Hefei National Laboratory for Physical Sciences at Microscale, CAS Key Laboratory of Innate Immunity and Chronic Disease, School of Basic Medical Sciences, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, China.
  • Hu S; Guangzhou Laboratory, Guangzhou International Biotech Island, Guangzhou, China.
  • Zhou S; Innovent Biologics (Suzhou) Co., Ltd., Suzhou, Jiangsu, China.
  • Wang Y; Innovent Biologics (Suzhou) Co., Ltd., Suzhou, Jiangsu, China.
  • Zhao J; Guangzhou Laboratory, Guangzhou International Biotech Island, Guangzhou, China.
  • Yuan D; State Key Laboratory of Respiratory Disease, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.
  • Liu L; Guangzhou Laboratory, Guangzhou International Biotech Island, Guangzhou, China.
  • Wu D; State Key Laboratory of Respiratory Disease, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.
  • Xu M; Innovent Biologics (Suzhou) Co., Ltd., Suzhou, Jiangsu, China.
  • Zhang F; Innovent Biologics (Suzhou) Co., Ltd., Suzhou, Jiangsu, China.
  • Zhu M; Innovent Biologics (Suzhou) Co., Ltd., Suzhou, Jiangsu, China.
  • Wu Z; Innovent Biologics (Suzhou) Co., Ltd., Suzhou, Jiangsu, China.
  • Cao X; Innovent Biologics (Suzhou) Co., Ltd., Suzhou, Jiangsu, China.
  • Ni M; Innovent Biologics (Suzhou) Co., Ltd., Suzhou, Jiangsu, China.
  • Ling X; Innovent Biologics (Suzhou) Co., Ltd., Suzhou, Jiangsu, China.
  • Wu Y; Innovent Biologics (Suzhou) Co., Ltd., Suzhou, Jiangsu, China.
  • Kuang Z; Innovent Biologics (Suzhou) Co., Ltd., Suzhou, Jiangsu, China.
  • Hu M; Innovent Biologics (Suzhou) Co., Ltd., Suzhou, Jiangsu, China.
  • Li J; Innovent Biologics (Suzhou) Co., Ltd., Suzhou, Jiangsu, China.
  • Li X; Innovent Biologics (Suzhou) Co., Ltd., Suzhou, Jiangsu, China.
  • Guo X; Innovent Biologics (Suzhou) Co., Ltd., Suzhou, Jiangsu, China.
  • Xu T; Innovent Biologics (Suzhou) Co., Ltd., Suzhou, Jiangsu, China.
  • Jiang H; Innovent Biologics (Suzhou) Co., Ltd., Suzhou, Jiangsu, China.
  • Gao C; Jiangsu Provincial Center for Disease Control and Prevention, Nanjing, China.
  • Yu M; Department of Infectious Diseases, The Third People's Hospital of Changzhou, Changzhou, China.
  • Liu J; Department of Medical Oncology, First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, Zhejiang Province, China.
  • Zhong N; Innovent Biologics (Suzhou) Co., Ltd., Suzhou, Jiangsu, China.
  • Zhou J; Innovent Biologics (Suzhou) Co., Ltd., Suzhou, Jiangsu, China.
  • Huang JA; Innovent Biologics (Suzhou) Co., Ltd., Suzhou, Jiangsu, China.
  • Jin T; Guangzhou Laboratory, Guangzhou International Biotech Island, Guangzhou, China.
  • He J; State Key Laboratory of Respiratory Disease, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.
J Clin Invest ; 132(4)2022 Feb 15.
Article in English | MEDLINE | ID: covidwho-1705312
ABSTRACT
Many SARS-CoV-2 neutralizing antibodies (nAbs) lose potency against variants of concern. In this study, we developed 2 strategies to produce mutation-resistant antibodies. First, a yeast library expressing mutant receptor binding domains (RBDs) of the spike protein was utilized to screen for potent nAbs that are least susceptible to viral escape. Among the candidate antibodies, P5-22 displayed ultrahigh potency for virus neutralization as well as an outstanding mutation resistance profile. Additionally, P14-44 and P15-16 were recognized as mutation-resistant antibodies with broad betacoronavirus neutralization properties. P15-16 has only 1 binding hotspot, which is K378 in the RBD of SARS-CoV-2. The crystal structure of the P5-22, P14-44, and RBD ternary complex clarified the unique mechanisms that underlie the excellent mutation resistance profiles of these antibodies. Secondly, polymeric IgG enhanced antibody avidity by eliminating P5-22's only hotspot, residue F486 in the RBD, thereby potently blocking cell entry by mutant viruses. Structural and functional analyses of antibodies screened using both potency assays and the yeast RBD library revealed rare, ultrapotent, mutation-resistant nAbs against SARS-CoV-2.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: Broadly Neutralizing Antibodies / SARS-CoV-2 / COVID-19 / Antibodies, Viral Type of study: Randomized controlled trials Topics: Variants Limits: Animals / Humans Language: English Year: 2022 Document Type: Article Affiliation country: JCI154987

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Broadly Neutralizing Antibodies / SARS-CoV-2 / COVID-19 / Antibodies, Viral Type of study: Randomized controlled trials Topics: Variants Limits: Animals / Humans Language: English Year: 2022 Document Type: Article Affiliation country: JCI154987